Evidence map›Paper›PMID 28033584›Full record

ArticleJournal of chromatography. B, Analytical technologies in the biomedical and life sciences2017

Identification, bioactivity evaluation and pharmacokinetics of multiple components in rat serum after oral administration of Xian-Ling-Gu-Bao capsule by ultra performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry.

Zhi-Hong Yao, Zi-Fei Qin, Liang-Liang He, Xin-Luan Wang, Yi Dai, Ling Qin, Frank J Gonzalez, Wen-Cai Ye, Xin-Sheng Yao

Open access · greenAbstract read
In one paragraph

Article in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Metabolic profiling of corylin in vivo and in vitro.Journal of pharmaceutical and biomedical analysis · 2018
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Zhi-Hong YaoCollege of Pharmacy, Jinan University, Guangzhou, 510632, PR China. Electronic address: tyaozh@jnu.edu.cn.
Zi-Fei QinCollege of Pharmacy, Jinan University, Guangzhou, 510632, PR China.
Liang-Liang HeCollege of Pharmacy, Jinan University, Guangzhou, 510632, PR China.
Xin-Luan WangMusculoskeletal Research Laboratory, Department of Orthopaedics and Traumatology, Chinese University of Hong Kong, Shatin, N.T. Hong Kong SAR, PR China; Translational Medicine R&D Centre, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518057, PR China.
Yi DaiCollege of Pharmacy, Jinan University, Guangzhou, 510632, PR China. Electronic address: daiyi1004@163.com.
Ling QinMusculoskeletal Research Laboratory, Department of Orthopaedics and Traumatology, Chinese University of Hong Kong, Shatin, N.T. Hong Kong SAR, PR China; Translational Medicine R&D Centre, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518057, PR China.
Frank J GonzalezLaboratory of Metabolism, Centre for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Wen-Cai YeCollege of Pharmacy, Jinan University, Guangzhou, 510632, PR China.
Xin-Sheng YaoCollege of Pharmacy, Jinan University, Guangzhou, 510632, PR China.
Jinan University · CN

Funding

Xenobiotic receptorsZIABC005562 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GONZALEZ, FRANK J · 2009 to 2025
$26.9M
Xenobiotic ReceptorsZIABC005708 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GONZALEZ, FRANK J · 2009 to 2025
$16.4M
Xenobiotic-Metabolizing EnzymesZ01BC005562 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GONZALEZ, FRANK J · 1996 to 2008
$1.3M
Intramural NIH HHS Z01 BC005562
6 · The paper itself

Abstract

The Xian-Ling-Gu-Bao capsule (XLGB) is a famous traditional Chinese medicine prescription (TCMP), which has proven effective in osteoporosis treatment. However, due to the lack of a dynamic XLGB profile, the in vivo pharmacokinetics of multiple bioactive components within this medicine remains unknown. In the present study, ultra-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry (UPLC/Q-TOF-MS) identified a total of eighteen prototypes (using reference standards) in rat serum after oral administration of XLGB. These prototypes were subsequently evaluated to ascertain their effects on the proliferation and alkaline phosphatase activity of UMR106 cells and the adipogenesis of 3T3-L1 cells. Furthermore, a rapid and sensitive UPLC/Q-TOF-MS method was developed and validated for simultaneous quantitative analysis of 11 prototypes in rat serum. Chromatographic separation was achieved using a Waters Acquity BEH C18 column (2.1×100mm, 1.7μm) and linear gradient elution employing a mobile phase consisting of water and acetonitrile (both containing 0.1% formic acid). All calibration curves showed excellent linearity (r

Indexed as

Administration, OralAnimalsChromatography, High Pressure LiquidDrugs, Chinese HerbalLinear ModelsMaleMass SpectrometryRatsRats, Sprague-DawleyReproducibility of ResultsSensitivity and SpecificityDrugs, Chinese Herbalxian ling gu baoBioactivity evaluationMain prototypesPharmacokineticsRat serumUPLC/Q-TOF-MSXian-Ling-Gu-Bao capsule

Identifiers

PMID28033584
PMCPMC6338342
OpenAlexW2567128258

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.